Suppr超能文献

在无导线经导管心脏起搏器中,起搏阈值和阻抗的组合预测了长期随访时非常高的起搏阈值。

Very high pacing thresholds during long-term follow-up predicted by a combination of implant pacing threshold and impedance in leadless transcatheter pacemakers.

机构信息

Arrhythmia Section, Hospital Clínic, Cardiovascular Clinic Institute, University of Barcelona, Barcelona, Catalonia, Spain.

Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

出版信息

J Cardiovasc Electrophysiol. 2020 Apr;31(4):868-874. doi: 10.1111/jce.14360. Epub 2020 Jan 29.

Abstract

BACKGROUND

Micra transcatheter pacemaker system (TPS) usually achieves low implant pacing threshold (IPT). However, IPT may increase in some patients during follow-up.

AIM

To apply implant parameters in predicting long-term occurrence of very high pacing threshold (VHPT) in patients with Micra-TPS.

METHODS

A cohort of 110 consecutive patients implanted with a Micra-TPS from 2014 to 2018 was evaluated at discharge and at 1, 12, 24, 36, and 48 months follow-up. VHPT was defined as greater than 2 V/0.24 ms. VHPT predictors were identified.

RESULTS

Micra-TPS was implanted successfully in 108 patients (98.2%). During a mean follow-up of 24 ± 16 months, 18 patients (16.7%) died of causes nonpacemaker-related, and 4 (3.8%) developed VHPT. Patients with VHPT had higher IPT and lower implant impedance than patients with non-VHPT: 1 ± 0.31 vs 0.55 ± 0.29 V/0.24 ms (P = .003) and 580 ± 59 vs 837 ± 232 Ω (P = .03), respectively. IPT and impedance had excellent discriminative power to predict VHPT (area under the curve: 0.85 ± 0.07 and 0.91 ± 0.05, respectively). Negative predictive value (NPV) of IPT ≤ 0.5 V/0.24 ms was 100%; positive predictive value (PPV) was 8% throughout follow-up. Implant impedance ≤ 600 Ω had NPV of 99% throughout follow-up, whereas PPV varied: 16%, 21%, 16%, and 28% at 1, 12, 24, and 36 months, respectively. Sequential combination of IPT greater than 0.5 V/0.24 ms and impedance ≤ 600 Ω improved PPV to 25%, 35%, 27%, and 44%, respectively, whereas NPV remained 99% throughout follow-up.

CONCLUSION

Despite favorable long-term electrical performance of Micra-TPS, a small percent of patients developed VHPT during follow-up. A sequential combination of IPT and impedance could allow the implanter to identify patients who will develop VHPT during long-term follow-up.

摘要

背景

Micra 经导管心脏起搏器系统(TPS)通常可实现较低的植入起搏阈值(IPT)。然而,在随访过程中,某些患者的 IPT 可能会升高。

目的

探讨植入参数对 Micra-TPS 患者长期出现极高起搏阈值(VHPT)的预测价值。

方法

回顾性分析 2014 年至 2018 年期间连续 110 例植入 Micra-TPS 的患者资料。在出院时及 1、12、24、36 和 48 个月时随访时评估患者。VHPT 定义为大于 2 V/0.24 ms。分析预测 VHPT 的相关因素。

结果

108 例患者(98.2%)成功植入 Micra-TPS。平均随访 24±16 个月期间,18 例(16.7%)患者因非起搏器相关原因死亡,4 例(3.8%)发生 VHPT。与非 VHPT 患者相比,VHPT 患者的 IPT 更高,植入阻抗更低:1±0.31 V/0.24 ms 比 0.55±0.29 V/0.24 ms(P=0.003)和 580±59 Ω 比 837±232 Ω(P=0.03)。IPT 和阻抗对预测 VHPT 具有良好的区分能力(曲线下面积:0.85±0.07 和 0.91±0.05)。IPT≤0.5 V/0.24 ms 的阴性预测值(NPV)为 100%;整个随访期间的阳性预测值(PPV)为 8%。植入阻抗≤600 Ω 的 NPV 为 100%,而整个随访期间的 PPV 分别为 16%、21%、16%和 28%。IPT 大于 0.5 V/0.24 ms 与阻抗≤600 Ω 的连续组合可使 PPV 分别提高至 25%、35%、27%和 44%,而 NPV 仍为 100%。

结论

尽管 Micra-TPS 具有良好的长期电性能,但在随访期间仍有一小部分患者发生 VHPT。IPT 和阻抗的连续组合可帮助植入医生识别出在长期随访中会发生 VHPT 的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验